Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

A two-year multicenter, retrospective 'real world' clinical setting study on the efficacy and safety of a trabecular scaffold (Hydrus) combined with phacoemulsification

Search Title by author or title

Session Details

Session Title: Glaucoma

Session Date/Time: Monday 09/10/2017 | 08:00-10:30

Paper Time: 09:24

Venue: Room 4.1

First Author: : A.Fea ITALY

Co Author(s): :    M. Rekas   L. Au                 

Abstract Details


To evaluate the efficacy and the safety of a novel trabecular bypass (Hydrus,Ivantis) combined with cataract surgery in a “real world” clinical setting Design: Retrospective, consecutive case series


Dipartimento di Scienze Chirurgiche – Clinica Oculistica di Torino – Torino, Italy Department of Ophthalmology, Military Institute of Medicine, Warsaw, Poland Manchester Royal Eye Hospital, Central Manchester Foundation Trust, Manchester, UK


Data on POAG patients who underwent a combined phacoemulsification and implant of the Hydrus (Ivantis) stent was analyzed. Data was collected pre-operatively and postoperatively through 24 months. Data included intraocular pressure (IOP), number of glaucoma medication (ngmeds), incidence of complications. Data were further analyzed considering patients with a pre-operative IOP<18 mmHg on meds and patients with IOP≥ 8 mm Hg.


92 eyes were included. Six patients had previous glaucoma surgeries. Mean baseline IOP was 19.4±4.4 mm Hg. Mean IOP was 15.5±2.7 mmHg, 15.7±2.5 mmHg at 1-2 years (p<0.001). The IOP drop was correlated to the baseline IOP (R2=0.72). The mean ngmeds (2.1) was significantly (p<0,001) reduced at one (0.6±1) and two years (0.7±1). 61% were medication free at two years. In patients with IOP≥18mmHg preoperatively the reduction of IOP and of ngmeds was higher. Two patients needed stent repositioning. One received Argon laser to unblock the stent and one patient underwent trabeculectomy.


the Hydrus implantation combined with cataract surgery safely and effectively lowers the IOP and medication use in a “real world” clinical setting with results comparable to previous randomized clinical trials. Patients with IOP≥18mmHg pre-operatively had better results.

Financial Disclosure:


Back to previous